

## PRESS RELEASE

innate pharma

---

### ANNUAL GENERAL MEETING OF JUNE 28, 2013

- All proposed resolutions were voted according to management's recommendations
- Pr. Michael Caligiuri was appointed as a new member of the Supervisory Board

#### Marseille, France, July 1, 2013

---

Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces that during its Annual General Meeting ("AGM") which took place on June 28, 2013, in Marseille, France, a number of 21,278,689 votes were expressed out of a total of 38,055,614 shares with voting rights, representing a quorum of 55.9%. All resolutions were voted in accordance with the management's recommendations. Details of the votes are available on Innate Pharma's website, in the [investors section](#).

During the AGM, Pr. Michael Caligiuri, CEO of The James Cancer Hospital and Director of the Comprehensive Cancer Center at The Ohio State University, was appointed as a new member of the Supervisory Board.


The professor is a leukemia physician and a laboratory scientist focused on innate immunity (natural killer cell biology) and genesis and treatment of leukemia. Pr. Caligiuri attended *Stanford University Medical School* and trained in Internal Medicine, Oncology, Bone Marrow Transplantation, and Immunology at *Harvard's Brigham and Women's Hospital* and *The Dana Farber Cancer Institute*. His laboratory is comprised of 30 people and well-funded by the *United States National Cancer Institute*. Over 1000 patients have been accrued to clinical trials designed or co-designed by Pr. Caligiuri.

O.G.B.B.A. van Herk B.V, a Dutch investment fund, was appointed as a new observer on the Supervisory Board. As at the date of the AGM, O.G.B.B.A. van Herk B.V held 8.1% of Innate Pharma.

*"We are very pleased to have Michael Caligiuri join our board as a new independent member" said Gilles Brisson, Chairman of the Supervisory board of Innate Pharma. "Michael is a renowned immunotherapy expert and a pioneer in the booming field of immuno-oncology; his medical experience will be very valuable and highly complementary of the different current profiles". He added: "The presence of O.G.B.B.A. van Herk B.V as a new significant shareholder in the capital of Innate Pharma is also a very good news and a testimony of their support to the Company".*

Today, the Supervisory board of Innate Pharma is composed of:

- Gilles Brisson, Chairman, Independent Board member;
- Irina Staatz-Granter, Vice- Chairman, Independent Board member;
- Novo Nordisk A/S, represented by Per Falk, Board member;
- Patrick Langlois, Board member;
- Philippe Pouletty, Independent Board member;



## PRESS RELEASE

innate pharma

---

- Michael Caligiuri, Independent Board member;
- Bernard Malissen, Chairman of the Scientific Committee, Observer;
- Fond Stratégique d'Investissement (« FSI »), represented by Olivier Martinez, Observer;
- O.G.B.B.A. van Herk B.V, represented by Dharminder Chahal, Observer.

### About Innate Pharma:

Innate Pharma S.A. is a biopharmaceutical company developing first-in-class immunotherapy drugs for cancer and inflammatory diseases.

The Company specializes in the development of new monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Its innovative approaches have led to licensing agreements with Novo Nordisk A/S and Bristol-Myers Squibb.

Incorporated in 1999 and listed on NYSE-Euronext in Paris in 2006, Innate Pharma is based in Marseilles, France, and had 83 employees as at March 31, 2013.

Learn more about Innate Pharma at [www.innate-pharma.com](http://www.innate-pharma.com).

### Practical Information about Innate Pharma shares:

**ISIN code** FR0010331421  
**Ticker code** IPH

### Disclaimer:

This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the *Document de Reference* prospectus filed with the AMF, which is available on the AMF website (<http://www.amf-france.org>) or on Innate Pharma's website.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

### For additional information, please contact:

**Innate Pharma**  
Laure-Hélène Mercier  
Director, Investor Relations  
Phone: +33 (0)4 30 30 30 87  
[investors@innate-pharma.com](mailto:investors@innate-pharma.com)

**ATCG Press**  
Marielle Bricman  
Mob.: +33 (0)6 26 94 18 53  
[mb@atcg-partners.com](mailto:mb@atcg-partners.com)